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March 2012892 Letters to the Editorwith CLI requires evaluation by specialists. This evaluation should
also consider the major decrease in quality of life after major
amputation, the decreased productivity associated with major am-
putation, newly required nursing care costs, and economic and
time burdens on the patient’s family. However, we believe that
cilostazol has been sufficiently evaluated and should be used in
patients in whom the drug is expected to be particularly effective
for major event reduction (age 75 years old, ambulatory, not
receiving dialysis, Rutherford class V), as suggested in Fig 6 of our
original article.1
Yoshimitsu Soga, MD
Department of Cardiology
Kokura Memorial Hospital
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Regarding “Basilic vein transposition versus
biosynthetic prosthesis as vascular access for
hemodialysis”
Morosetti et al present a study concluding that, when possible,
brachiobasilic arteriovenous fistula (BBAVF) should be created in
preference to the insertion of an arteriovenous graft (AVG).1 This
conclusion concurs with those of other studies.2
The AVG group in the current study combines forearm loop
AVGs (FLAVG) and brachioaxillary AVGs (BAAVG). This group-
ing should be considered to be inappropriate, as FLAVG and
BAAVG are not directly comparable. The majority of AVG failures
are due to stenosis at the venous anastomosis. These stenoses do
not lead to draining vein occlusion, or adversely affect the arterial
inflow.3 The placement of a FLAVG should not therefore prevent
the future creation of a BBAVF. The formation of a BBAVF,
however, does preclude the formation of a FLAVG as, following
occlusion of the basilic vein, only BAAVG can be considered. It is
perhaps more appropriate to consider the FLAVG as a halfway
house between a primary access (radiocephalic or brachiocephalic
AVF), and a secondary access (BBAVF or BAAVG), and as such
FLAVGs should be considered separately to BAAVGs.
A large multicenter randomized study directly comparing
BBAVF and FLAVG showed that although primary patency rates
are lower and complication rates higher in grafts, secondary pa-
tency rates were equivalent between the two groups.4
Although primary and secondary patency data in isolation are
important for assessing the efficacy of a vascular access interven-
tion, just as important is the effect that the intervention has on
subsequent access attempts and longevity. Thus, as described
above, as FLAVG does not preclude BBAVF formation and does
not reduce venous capital, it may therefore increase the longevity
of total vascular access attempts in that arm. Conversely, creation
of BBAVF precludes FLAVG, reduces venous capital, and thus
reduces the overall longevity of vascular access in that limb.
Finally, it is noteworthy that FLAVG with modern self-sealing
grafts can allow almost immediate vascular access for emergency
dialysis and act as a medium-term bridge to more definitive dialysis
access.
Philip James Yates, MD, MRCS (Ed)
Department of Transplant Surgery
Queen Elizabeth Hospital
Birmingham, United Kingdom
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The comparison between the present study1 and those re-
orted in the other references2,3 is not correct. In fact, they are
etrospective studies, while our study is a randomized one (so the
tatistical power of our results is stronger despite the minor sample
ize).
Our data are not so far different from those reported in the
urrent literature on this topic. In fact, most of the authors
onclude that native vascular accesses show a better primary pa-
ency when compared with the prosthetic ones. Moreover, most of
he authors consider prosthetic vascular accesses (VA) as a whole as
ne single group for follow-up, regardless of the different config-
rations and insertion sites. This is the reason why we gathered
rosthetic VA in one batch as well.
Basilic vein stenosis and consequent thrombosis, which could
evelop after a forearm loop arterovenous graft implantation, in
ost cases makes basilic vein itself fully unusable for transposition,
nd in any case, it reduces the vessel length (which is itself a limit to
ransposition because often the vascular segment available for
eedle puncturing is not so long).
The randomized study by Keuter et al4 compares “autogenous
rachial-basilic fistula in the upper arm (BBAVF) or a prosthetic
rachial-antecubital forearm loop (PTFE loop),” which are exactly
he same VA kinds we considered. This puts in evidence the fact that
orearm arterovenous grafts (AVGs) and basilic vein transposition
epresent two concurring chances for the surgeon in compromised
atients. This study concludes that primary patency (PP) is lower for
VGs. In our study, we found that PP was higher for BBAVF; that is
xactly the same conclusion. Similarly, results regarding secondary
atency are superimposable between the two studies.
As regards the impact of a specific kind of VA set-up on
ubsequent attempts and longevity, keeping in mind the need to
pare patient’s vessels, we could state that a loop AVG could be
mplanted anyway after BBAVF thrombosis, using a brachial artery
omitans vein.
Finally, we fully agree on the possibility of using AVGs as an
mmediate vascular access in selected patients. In fact, in our
onclusions, we state that “given the shorter time to use, in
ubjects showing compromised clinical conditions and in who a
emporary VA is not reliable, AVG could be the first choice.”
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